Comparative Analysis of the Effects of a Novel Vacuolar Adenosine 5′-Triphosphatase Inhibitor, FR202126, and Doxycycline on Bone Loss Caused by Experimental Periodontitis in Rats

• Autores: K. Niikura
• Localización: Journal of periodontology, ISSN 0022-3492, Vol. 77, Nº. 7, 2006, págs. 1211-1216
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Comparative Analysis of the Effects of a Novel Vacuolar Adenosine 5′-Triphosphatase Inhibitor, FR202126, and Doxycycline on Bone Loss Caused by Experimental Periodontitis in Rats K. Niikura* *Data Management and Regulatory Support Department, Astellas Research Service, Ibaraki, Japan.

    Correspondence: Dr. K. Niikura, Data Management and Regulatory Support Department, Astellas Research Service, 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan. Fax: 81-29-852-5391; e-mail: kazuaki.niikura@jp.astellas.com.

    Background: Doxycycline is reported to inhibit alveolar bone destruction by blocking matrix metalloproteinases (MMPs). Nevertheless, MMPs are not involved in osteoclastic bone resorption; osteoclasts directly resorb bone. An acidic microenvironment, which is formed by vacuolar adenosine 5′-triphosphatase (V-ATPase) expressed in the plasma membranes of osteoclasts, is indispensable for osteoclastic bone resorption. In the present study, we investigated the potential role of the acidic environment on periodontal bone destruction using a novel and specific V-ATPase inhibitor, FR202126, which we compared to doxycycline.

    Methods: Inhibitory activity against in vitro bone resorption was examined by measuring the Ca2+ release from murine calvariae cultured for 6 days, which were treated with interleukin-1 (IL-1), IL-6, or parathyroid hormone. Experimental periodontitis was induced by a ligature wire tied around the contact between the first and second maxillary molars of male Wistar rats. FR202126 and doxycycline were administered orally once daily for 6 days. Seven days after tying, the maxillae were dissected and mesiodistal longitudinal paraffin sections, including interdental alveolar bone, were processed for histopathologic analysis.

    Results: FR202126 inhibited bone resorption almost completely in calvaria cultures induced by three stimulators, whereas doxycycline was unable to prevent in vitro bone resorption. Oral administration of FR202126 significantly prevented alveolar bone loss in experimental periodontitis. However, doxycycline did not inhibit alveolar bone destruction.

    Conclusion: These results suggest that an acidic microenvironment plays a more important role than MMPs in periodontal alveolar bone destruction and that V-ATPase inhibitors may offer a new approach to the treatment of periodontal disease.

    KEYWORDS: Alveolar bone loss, doxycycline, matrix metalloproteinase, osteoclast, vacuolar ATPase Cited by Geoffrey Burnstock, Timothy R. Arnett and Isabel R. Orriss. (2013) Purinergic signalling in the musculoskeletal system. Purinergic Signalling 9, 541-572.

    Online publication date: 1-Dec-2013.

    CrossRef A. Qin, T.S. Cheng, N.J. Pavlos, Z. Lin, K.R. Dai and M.H. Zheng. (2012) V-ATPases in osteoclasts: Structure, function and potential inhibitors of bone resorption. The International Journal of Biochemistry & Cell Biology 44, 1422-1435.

    Online publication date: 1-Sep-2012.

    CrossRef Rui Xie, Anne Marie Kuijpers-Jagtman and Jaap C Maltha. (2011) Inflammatory responses in two commonly used rat models for experimental tooth movement: Comparison with ligature-induced periodontitis. Archives of Oral Biology 56, 159-167.

    Online publication date: 1-Feb-2011.

    CrossRef Hui Zhao, Alexei Alexeev, Vrushali Sharma, Lorenzo Dave T. Guzman and Krzysztof Bojanowski. (2008) Effect of SBD.4A - a defined multicomponent preparation of Angelica sinensis - in periodontal regeneration models. Phytotherapy Research 22, 923-928.

    Online publication date: 1-Jul-2008.

    CrossRef Sengen Sun. (2008) Bone disease drug discovery: examining the interactions between osteoblast and osteoclast. Expert Opinion on Therapeutic Targets 12:10.1517/ett.2008.12.issue-2, 239-251.

    Online publication date: 1-Feb-2008.

    CrossRef